NCT00819832 · ADVERSE EVENTS

Adverse events

Anderson Circulating Tumor Cell Burden (CTCB) Study · Source last updated 2023-03-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 15 months
Other-event reporting threshold: 5%

No patients were enrolled in other groups or Phase II.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Phase 1 Group 1 Vertebroplasty Vertebroplasty	0 / 3	0 / 3	Not reported / Not reported
Phase 1 Group 2 Kyphoplasty Kyphoplasty	0 / 0	0 / 0	Not reported / Not reported
Phase 2 Group 1 Vertebroplasty Vertebroplasty	0 / 0	0 / 0	Not reported / Not reported
Phase 2 Group 2 Vertebroplasty +Cavity SpineWand Vertebroplasty with Cavity SpineWand	0 / 0	0 / 0	Not reported / Not reported
Phase 2 Group 3 Kyphoplasty Kyphoplasty	0 / 0	0 / 0	Not reported / Not reported
Phase 2 Group 4 Kyphoplasty + Cavity SpineWand Kyphoplasty with Cavity SpineWand	0 / 0	0 / 0	Not reported / Not reported

Group identifiers: EG000: Phase 1 Group 1 Vertebroplasty · EG001: Phase 1 Group 2 Kyphoplasty · EG002: Phase 2 Group 1 Vertebroplasty · EG003: Phase 2 Group 2 Vertebroplasty +Cavity SpineWand · EG004: Phase 2 Group 3 Kyphoplasty · EG005: Phase 2 Group 4 Kyphoplasty + Cavity SpineWand

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

No patients were enrolled in other groups or Phase II.

event Groups

description
Vertebroplasty
id
EG000
other Num Affected
0
other Num At Risk
3
serious Num Affected
0
serious Num At Risk
3
title
Phase 1 Group 1 Vertebroplasty
description
Kyphoplasty
id
EG001
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Phase 1 Group 2 Kyphoplasty
description
Vertebroplasty
id
EG002
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Phase 2 Group 1 Vertebroplasty
description
Vertebroplasty with Cavity SpineWand
id
EG003
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Phase 2 Group 2 Vertebroplasty +Cavity SpineWand
description
Kyphoplasty
id
EG004
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Phase 2 Group 3 Kyphoplasty
description
Kyphoplasty with Cavity SpineWand
id
EG005
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Phase 2 Group 4 Kyphoplasty + Cavity SpineWand

frequency Threshold

time Frame

15 months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice